Could supplements be the next big opportunity in the GLP-1 weight-loss drug boom?

Tłumaczenie nie jest jeszcze gotowe. Wyświetlamy oryginalny artykuł.

Supplements could be the next major sector to benefit from the weight-loss drug boom, Novonesis CEO told CNBC on Monday, as the biosolutions company explores whether microbiome products can help patients on popular GLP-1 medicines. "We have scientific evidence that [is] going to support the patients [on] GLP-1s feeling better, as a companion during the treatment," CEO Ester Baiget told "Squawk Box Europe," referencing an ongoing study with Novo Nordisk . GLP-1 medications and dietary supplements, such as those being developed by Novonesis, could play complementary roles in managing obesity and supporting longer-term health, she argued.